An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer.

ABSTRACT: Tumor-specific antigens (TSA) are central elements in the immune control of cancers. To systematically explore the TSA genome, we developed a computational technology called heterogeneous expression profile analysis (HEPA), which can identify genes relatively uniquely expressed in cancer cells in contrast to normal somatic tissues. Rating human genes by their HEPA score enriched for clinically useful TSA genes, nominating candidate targets whose tumor-specific expression was verified by reverse transcription PCR (RT-PCR). Coupled with HEPA, we designed a novel assay termed protein A/G-based reverse serological evaluation (PARSE) for quick detection of serum autoantibodies against an array of putative TSA genes. Remarkably, highly tumor-specific autoantibody responses against seven candidat

SUBMITTER: Xu QW 

PROVIDER: S-EPMC3525759 | biostudies-literature | 2012 Dec

REPOSITORIES: biostudies-literature